San Francisco, California, July 05, 2017: TMR Research in its latest report, studies the global anticonvulsants for neuropathic pain market. The report is titled “Anticonvulsants for Neuropathic Pain Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025.” The treatment for chronic pain resulting from an injury or due to any disease pertaining to the central or peripheral nervous system is a challenge for doctors as conventional therapies have not been effective to treat these neuropathic pains. However, due to the similarities between the symptoms observed in the neuropathic pain models and epilepsy models, anticonvulsants are increasingly being used for the managing neuropathic pain conditions. This is one of the key factors driving the anticonvulsants for neuropathic pain market.
Carbamazepine continues to be the most popular anticonvulsant prescribed by doctors for neuropathic pain. Depomed’s Gralise and XenoPort’s Horizant are some of the relatively newer anticonvulsants drugs introduced in 2011 and 2012 respectively. Moreover, new anticonvulsants are also being introduced in the market for the treatment of neuropathic pain, and this is expected to drive the growth prospects of the global anticonvulsants for neuropathic pain market. As the role of anticonvulsants for treating neuropathic pain evolves and advancements and clinical trials are improving the opportunities in the market, healthy growth is expected during the forecast period.
One of the key factors fueling the growth of the anticonvulsants for neuropathic pain market is the rising incidences of patients with neuropathic pain. Growing use of generic drugs is also a factor boosting the growth of this market. High number of patients is refractory towards alternate treatment methods, which is also encouraging the demand for anticonvulsants for neuropathic pain management. Growing rates of polypharmacy and development of novel drugs are some of the other factors boosting the growth of this market. As existing drugs are giving positive results to only some patients and have several side effects, there is a need for new drug variants that are effective and less harmful. This is expected to drive market players towards research and development and act as opportunity for growth.
Some of the key players operating in the global anticonvulsants for neuropathic pain market are studied in the report. They are: Depomed Inc., Teva Pharmaceuticals, Janssen Pharmaceutical Inc., GlaxoSmithKline plc, Cephalon Inc., Novartis AG, Pfizer Inc., XenoPort Inc., and AbbVie Inc.